Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis

Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and Potential Biomarkers

(2016) Panagiota Economopoulou et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival

(2016) Jan Budczies et al.   GENES CHROMOSOMES & CANCER

Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas

(2016) Takashi Mukaigawa et al.   JOURNAL OF SURGICAL ONCOLOGY

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

(2016) Tanguy Y Seiwert et al.   LANCET ONCOLOGY

Correlation of PD-L1 Expression of Tumor Cells with Survival Outcomes after Radical Intensity-Modulated Radiation Therapy for Non-Metastatic Nasopharyngeal Carcinoma

(2016) Victor H. F. Lee et al.   PLoS One

Association between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma

(2016) Hae Su Kim et al.   Cancer Research and Treatment

Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma

(2015) M. Vassilakopoulou et al.   CLINICAL CANCER RESEARCH

Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013

(2015) Theo Vos et al.   LANCET

Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013

(2015)   LANCET

Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma

(2015) Jianwei Zhang et al.   MEDICAL ONCOLOGY

Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck

(2015) Julia Thierauf et al.   MELANOMA RESEARCH

Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy

(2015) Abhisek Swaika et al.   MOLECULAR IMMUNOLOGY

Associations among pretreatment tumor necrosis and the expression of HIF-1α and PD-L1 in advanced oral squamous cell carcinoma and the prognostic impact thereof

(2015) Tseng-Cheng Chen et al.   ORAL ONCOLOGY

Prognostic value of programmed cell death-ligand 1 expression in patients with non-small-cell lung cancer: evidence from an updated meta-analysis

(2015) Anyuan Zhong et al.   OncoTargets and Therapy

Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells

(2015) Joao Paulo Oliveira-Costa et al.   Oncotarget

PD-L1 and Survival in Solid Tumors: A Meta-Analysis

(2015) Pin Wu et al.   PLoS One

High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma

(2015) Yueh-Min Lin et al.   PLoS One

EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy

(2015) Wenfeng Fang et al.   Oncotarget

New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape

(2014) Deepak Mittal et al.   CURRENT OPINION IN IMMUNOLOGY

Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy

(2014) Kim A Reiss et al.   Immunotherapy

Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies

(2014) G. K. Philips et al.   INTERNATIONAL IMMUNOLOGY

The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck

(2014) Dan P. Zandberg et al.   ORAL ONCOLOGY

Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma

(2013) S. Lyford-Pike et al.   CANCER RESEARCH

Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors

(2013) J. Duraiswamy et al.   CANCER RESEARCH

PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer

(2012) C. Badoual et al.   CANCER RESEARCH

Cellular Constituents of Immune Escape within the Tumor Microenvironment

(2012) S. P. Kerkar et al.   CANCER RESEARCH

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma

(2011) Young-Ah Cho et al.   ORAL ONCOLOGY

New advances in molecular approaches to head and neck squamous cell carcinoma

(2010) Nivedita Sahu et al.   ANTI-CANCER DRUGS

B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance

(2010) J.-J. Park et al.   BLOOD

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells

(2008) T. Azuma et al.   BLOOD

Head and neck cancer

(2008) Athanassios Argiris et al.   LANCET